<DOC>
	<DOCNO>NCT00376948</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . Genistein may help gemcitabine erlotinib kill tumor cell make tumor cell sensitive drug . PURPOSE : This phase II trial study well give genistein together gemcitabine erlotinib work treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Genistein , Gemcitabine , Erlotinib Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 6-month survival rate patient locally advance metastatic pancreatic cancer treat genistein , gemcitabine hydrochloride , erlotinib hydrochloride . Secondary - Determine frequency objective tumor response rate patient . - Determine time treatment failure patient . - Determine effect baseline expression pAKT activation NF-kappaB survival patient treat regimen . - Determine overall time disease progression patient . - Estimate quantitative qualitative toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral genistein twice daily day -7 28 course 1 day 1-28 course . Patients also receive gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 oral erlotinib hydrochloride daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma Locally advance metastatic disease radiological evidence Must biopsy material consist 10 unstained slide paraffinembedded tissue block available correlative study No endocrine tumor lymphoma pancreas No history CNS ( central nervous system ) metastases PATIENT CHARACTERISTICS : SWOG ( Southwest Oncology Group ) performance status 01 Life expectancy ≥ 12 week Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Bilirubin &lt; 2.0 mg/dL AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &lt; 1.5 time upper limit normal Creatinine &lt; 1.5 mg/dL Albumin &gt; 2.5 g/dL INR ( international normalize ratio ) &lt; 1.3 ( absence ongoing treatment warfarin ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No condition would limit ability receive oral medication No requirement gastrostomy tube administration drug No serious concurrent systemic disorder , , opinion investigator , incompatible study No active second primary malignancy within past year except situ carcinoma cervix adequately treat basal cell carcinoma skin No allergy study drug PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy metastatic disease Prior adjuvant chemotherapy allow provide complete least 6 month ago No prior gemcitabine hydrochloride epidermal growth factor receptorinhibiting agent No concurrent chemotherapy , immunotherapy , tumordirected hormonal therapy , radiotherapy No concurrent investigational agent No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>